Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
Sponsor: Deciphera Pharmaceuticals, LLC
Summary
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.
Official title: A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) in Healthy Female Participants
Key Details
Gender
FEMALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-06
Completion Date
2026-08
Last Updated
2026-06-05
Healthy Volunteers
Yes
Conditions
Interventions
Vimseltinib
Administered orally
Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
Administered orally
Locations (1)
Nucleus Network
Saint Paul, Minnesota, United States